Amicus Therapeutics: Solid Fundamentals but Limited Upside Amid BioMarin Takeover, Justifying Hold Rating

Ritu Baral, an analyst from TD Cowen, maintained the Hold rating on Amicus. The associated price target remains the same with $14.50.

Ritu Baral has given his Hold rating due to a combination of factors, balancing solid operational performance with limited upside following the announced acquisition by BioMarin. Amicus preannounced fourth-quarter and full-year 2025 total product revenue modestly above expectations, with Galafold delivering a clear outperformance versus both TD Cowen and consensus estimates, while Pompe (PomOp) revenue came in roughly in line with broader Street expectations despite a slight shortfall versus the firm’s model. Overall, revenue growth remained strong on both a quarterly and annual basis and tracked well within management’s full-year guidance range, supported by a healthy year-end cash balance.
At the same time, the strategic landscape for the stock is now largely defined by BioMarin’s agreement to acquire Amicus for $14.50 per share in cash, with the deal already approved by both companies’ boards and expected to close by the second quarter of 2026, subject to shareholder and regulatory approvals. With a fixed takeout price and a clear M&A timeline, the scope for further meaningful appreciation in Amicus’s share price is constrained primarily to potential deal-spread dynamics and low-probability transaction risk, rather than fundamentals-driven multiple expansion. Consequently, while the underlying business continues to perform well, the risk/reward profile from here appears relatively balanced, supporting Baral’s decision to maintain a Hold rating.

Baral covers the Healthcare sector, focusing on stocks such as Insmed, Amicus, and Madrigal Pharmaceuticals. According to TipRanks, Baral has an average return of 40.7% and a 56.30% success rate on recommended stocks.

In another report released on January 22, Jefferies also downgraded the stock to a Hold with a $14.50 price target.